Crizotinib in MET deregulated or ROS1 rearranged pretreated non-small-cell lung cancer (METROS): a phase II, prospective, multicentre, two-arms trial

Lorenza Landi, Rita Chiari, Marcello Tiseo, Federica D'Incà, Claudio Dazzi, Antonio Chella, Angelo Delmonte, Laura Bonanno, Diana Giannarelli, Diego Luigi Cortinovis, Filippo De Marinis, Gloria Borra, Alessandro Morabito, Cesare Gridelli, Domenico Galetta, Fausto Barbieri, Francesco Grossi, Enrica Capelletto, Gabriele Minuti, Francesca MazzoniClaudio Verusio, Emilio Bria, Greta Alì, Rossella Bruno, Agnese Proietti, Gabriella Fontanini, Lucio Crinò, Federico Cappuzzo

Research output: Contribution to journalArticle

Fingerprint Dive into the research topics of 'Crizotinib in MET deregulated or ROS1 rearranged pretreated non-small-cell lung cancer (METROS): a phase II, prospective, multicentre, two-arms trial'. Together they form a unique fingerprint.

Medicine & Life Sciences